Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Dynavax Technologies Stock Is Soaring Today


Shares of Dynavax Technologies (NASDAQ: DVAX) are on the move after the company's vaccine adjuvant was featured in a positive clinical trial readout. Investors excited about the results have pushed the biotech stock 26.6% higher as of 12:02 p.m. EDT on Wednesday. 

Today, Dynavax's collaboration partner, Clover Biopharmaceuticals, reported positive results from the pivotal Spectra trial with Clover's COVID-19 vaccine candidate, SCB-2019. This is a protein-based vaccine that employs a booster, or adjuvant, from Dynavax. 

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments